Rheavita Closes Eur 2.5 Million Series A Financing Co-Led By Novalis Biotech Acceleration And Pmv
Jun 02, 2021•about 4 years ago
Amount Raised
€2.5 Million
Round Type
series a
Description
RheaVita, a company pioneering continuous freeze-drying technology for biopharmaceutical products, announced today that the company has closed a EUR 2.5 million Series A Financing. The round was co-led by Novalis Biotech Acceleration and Participatie Maatschappij Vlaanderen (PMV). Concurrent with the financing, Kjell Mortier from Novalis Biotech Acceleration and Stefan De Waele of PMV will join RheaVita’s Board of Directors.